Clinical Trial: A Phase I SAD/MAD and Liver Effect Study of Vitalangio in Venous Thromboembolism Patients .

U.S., June 2 -- ClinicalTrials.gov registry received information related to the study (NCT07618351) titled 'A Phase I SAD/MAD and Liver Effect Study of Vitalangio in Venous Thromboembolism Patients .' on May 17.

Brief Summary: The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a new drug, Vitalangio1, in healthy male and female volunteers aged 18 to 55 years old.

The main questions it aims to answer are:

What is the safety and tolerability profile of Vitalangio1 following single and multiple-dose administrations? What are the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of Vitalangio1, and how does food intake affect its absorption and drug metabolism? Resea...